RESEARCH-USE BIOSIMILAR ANTIBODY
Daxdilimab
Monoclonal antibody · IgG1
Daxdilimab (MEDI7734; VIB7734) is a monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7) that depletes plasmacytoid dendritic cells and reduces IFN1 production by binding to the plasmacytoid dendritic cell-specific surface molecule ILT7 and recruiting effector natural killer cells. Daxdilimab (MEDI7734; VIB7734) can be used for research on systemic lupus erythematosus, systemic sclerosis, and polymyositis.
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Daxdilimab (MEDI7734; VIB7734) is a monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7) that depletes plasmacytoid dendritic cells and reduces IFN1 production by binding to the plasmacytoid dendritic cell-specific surface molecule ILT7 and recruiting effector natural killer cells. Daxdilimab (MEDI7734; VIB7734) can be used for research on systemic lupus erythematosus, systemic sclerosis, and polymyositis.
Daxdilimab is a recombinant research-use antibody directed against LILRA4.